Impact of prenatal maternal depression on gestational length: post hoc analysis of a randomized clinical trial

Elysia Poggi Davis; Catherine H Demers; LillyBelle Deer; Robert J Gallop; M Camille Hoffman; Nancy Grote; Benjamin L Hankin

doi:10.1016/j.eclinm.2024.102601

Impact of prenatal maternal depression on gestational length: post hoc analysis of a randomized clinical trial

EClinicalMedicine. 2024 Apr 22:72:102601. doi: 10.1016/j.eclinm.2024.102601. eCollection 2024 Jun.

Authors

Elysia Poggi Davis^{1

2}, Catherine H Demers^{1

3}, LillyBelle Deer¹, Robert J Gallop⁴, M Camille Hoffman⁵, Nancy Grote⁶, Benjamin L Hankin⁷

Affiliations

¹ Department of Psychology, University of Denver, Denver, CO, USA.
² Department of Pediatrics, University of California, Irvine, CA, USA.
³ Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
⁴ Department of Mathematics, West Chester University, West Chester, PA, USA.
⁵ Department of Obstetrics and Gynecology, Division of Maternal and Fetal Medicine, University of Colorado Denver School of Medicine, Aurora, CO, USA.
⁶ School of Social Work, University of Washington, Seattle, WA, USA.
⁷ Department of Psychology, University of Illinois at Urbana-Champaign, Champaign, IL, USA.

Abstract

Background: Shortened gestation is a leading cause of childhood morbidity and mortality with lifelong consequences for health. There is a need for public health initiatives on increasing gestational age at birth. Prenatal maternal depression is a pervasive health problem robustly linked via correlational and epidemiological studies to shortened gestational length. This proof-of-concept study tests the impact of reducing prenatal maternal depression on gestational length with analysis of a randomized clinical trial (RCT).

Methods: Participants included 226 pregnant individuals enrolled into an RCT and assigned to receive either interpersonal psychotherapy (IPT) or enhanced usual care (EUC). Recruitment began in July 2017 and participants were enrolled August 10, 2017 to September, 8 2021. Depression diagnosis (Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; DSM 5) and symptoms (Edinburgh Postnatal Depression Scale and Symptom Checklist) were evaluated at baseline and longitudinally throughout gestation to characterize depression trajectories. Gestational dating was collected based on current guidelines via medical records. The primary outcome was gestational age at birth measured dichotomously (≥39 gestational weeks) and the secondary outcome was gestational age at birth measured continuously. Posthoc analyses were performed to test the effect of reducing prenatal maternal depression on gestational length. This trial is registered with ClinicalTrials.gov (NCT03011801).

Findings: Steeper decreases in depression trajectories across gestation predicted later gestational age at birth, specifically an increase in the number of full-term babies born ≥39 gestational weeks (EPDS linear slopes: OR = 1.54, 95% CI 1.10-2.16; and SCL-20 linear slopes: OR = 1.67, 95% CI 1.16-2.42). Causal mediation analyses supported the hypothesis that participants assigned to IPT experienced greater reductions in depression symptom trajectories, which in turn, contributed to longer gestation. Supporting mediation, the natural indirect effect (NIE) showed that reduced depression trajectories resulting from intervention were associated with birth ≥39 gestational weeks (EPDS, OR = 1.65, 95% CI 1.02-2.66; SCL-20, OR = 1.85, 95% CI 1.16-2.97).

Interpretation: We used a RCT design and found that reducing maternal depression across pregnancy was associated with lengthened gestation.

Funding: This research was supported by the NIH (R01 HL155744, R01 MH109662, R21 MH124026, P50 MH096889).

Keywords: Birth outcome; Depression; Gestational age at birth (GAB); Prenatal; Randomized clinical trial (RCT).

Associated data

ClinicalTrials.gov/NCT03011801